As Xi Jinping and Donald Trump meet in Washington, they have plenty on their plate including AI, Taiwan, Iran and other issues. One thing that wont be at the forefront will be biotechnology. Lex argues that China’s booming biotech sector is a win win for both China and the United States and it is in U.S. interest to let China continue its drug innovation without any punitive actions. Lex argues that letting China do cross-border licensing partnerships will help global biotech companies make better, cheaper drugs for the world.

Full opinion : Lex from Financial Times argues that Biotechnology is one space that U.S. can let China win.